Todd Simpson
Director/Board Member chez Washington Biotechnology & Biomedical Association
Profil
Todd E. Simpson est actuellement président de Neoleukin Therapeutics, Inc. et directeur financier de Seagen Inc. M. Simpson est également membre du conseil d'administration de Cascadian Therapeutics, Inc. et de la Washington Biotechnology & Biomedical Association. Dans sa carrière antérieure, il a occupé les postes de directeur financier et de vice-président des finances et de l'administration chez Vericel Corp, de trésorier chez Integra LifeSciences Holdings Corp et de directeur financier et vice-président de Telios Pharmaceuticals, Inc. (une filiale d'Integra LifeSciences Holdings Corp.), directeur financier et vice-président des finances et de l'administration chez AmpliPhi Biosciences Corp. et directeur chez Ernst & Young LLP. Il est titulaire d'un diplôme de premier cycle de l'université d'État de l'Oregon.
Postes actifs de Todd Simpson
Sociétés | Poste | Début |
---|---|---|
Washington Biotechnology & Biomedical Association | Director/Board Member | 25/04/2017 |
Inovia Capital (US), Inc. | Consultant / Advisor | 01/01/2017 |
Anciens postes connus de Todd Simpson
Sociétés | Poste | Fin |
---|---|---|
SEAGEN INC. | Director of Finance/CFO | 14/12/2022 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/10/2005 |
VERICEL CORPORATION | Director of Finance/CFO | 01/10/2001 |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01/10/2001 |
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Treasurer | 01/12/1995 |
Formation de Todd Simpson
Oregon State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | Health Technology |
VERICEL CORPORATION | Health Technology |
Entreprise privées | 8 |
---|---|
Telios Pharmaceuticals, Inc.
Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Integra LifeSciences Holdings Corp., Telios Pharmaceuticals, Inc. is a pharmaceutical company focused on research. The private company is based in San Diego, CA. The company was founded by Iain David Dukes, Erkki Ruoslahti. Telios Pharmaceuticals was acquired by Integra LifeSciences Holdings Corp. on August 17, 1995 for $35 million. | Health Technology |
AmpliPhi Biosciences Corp.
AmpliPhi Biosciences Corp. BiotechnologyHealth Technology AmpliPhi Biosciences Corp. clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. Its products include AB-SA01 and AB-PA01, which targets staphylococcus aureus and pseudomonas aeruginosa. The company was founded in March 1989 and is headquartered in San Diego, CA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Washington Biotechnology & Biomedical Association | |
Cascadian Therapeutics LLC
Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Cascadian Therapeutics LLC is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutic products for the treatment of cancer. Its product ONT-380, is an orally active and selective small-molecule HER2 inhibitor. The firm also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Bothell, WA. | Health Technology |
Inovia Capital (US), Inc. | Finance |